Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy

Background Hypercalcemia of malignancy (HCM), a major metabolic complication of cancer, is often managed with bisphosphonates (BP) and, increasingly, with denosumab. We aimed to compare the effectiveness and safety of denosumab with that of BP, with or without calcitonin, in treating HCM. Methods Th...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Sung Hye Kong, Seung Shin Park, Jung Hee Kim, Sang Wan Kim, Se Hyun Kim, Jee Hyun Kim, Chan Soo Shin
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Korean Endocrine Society 2025-04-01
Cyfres:	Endocrinology and Metabolism
Pynciau:	calcitonin denosumab diphosphonates hypercalcemia safety treatment outcome
Mynediad Ar-lein:	http://e-enm.org/upload/pdf/enm-2024-2132.pdf
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!